{"id":"W2399066128","doi":"10.1158/1538-7445.sabcs15-p4-13-14","title":"Abstract P4-13-14: Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Capecitabine; Discontinuation; Fulvestrant; Everolimus; Internal medicine; Metastatic breast cancer; Regimen; Oncology; Aromatase inhibitor; Cancer; Hazard ratio; Tolerability; Breast cancer; Anastrozole; Aromatase; Adverse effect; Tamoxifen; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001732239,0.0003633182,0.0006078491,0.001870143,0.0008053136,0.001273148,0.001019492,0.0006891859,0.002971225],"category_scores_gemma":[0.005660974,0.0005075966,0.001305968,0.003588915,0.0004317167,0.0008169027,0.000800291,0.001213273,0.0006442543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001413622,"about_ca_system_score_gemma":0.001390628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01119605,"about_ca_topic_score_gemma":0.008220544,"domain_scores_codex":[0.9975915,0.0004506118,0.0006115208,0.0005517259,0.0005674953,0.000227197],"domain_scores_gemma":[0.9911886,0.001197381,0.005757913,0.0004541145,0.0008267426,0.0005752592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001060874,0.0001968204,0.9957792,0.00008107246,0.0002814691,0.0001235651,0.0001050881,0.00007663278,0.000160173,0.00007316376,0.0007886998,0.001273359],"study_design_scores_gemma":[0.0001695495,0.0005119303,0.9951347,0.0000849987,0.0003774748,0.0005763519,0.0003799275,0.0007611327,0.000204647,0.00009239079,0.001685766,0.00002122242],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985219,0.0006025104,0.0002761523,0.0001198931,0.0000172015,0.0002323474,0.01248897,0.000009947026,0.001033948],"genre_scores_gemma":[0.9899301,0.0002315767,0.0002532556,0.0001841356,0.00003747109,0.0003303038,0.008586704,0.000007982301,0.0004384774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01119605,"threshold_uncertainty_score":0.02226174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07351609551178608,"score_gpt":0.4190183709053069,"score_spread":0.3455022753935208,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}